MultiValent Biotherapies is developing a peptide-like drug conjugate that hits two validated targets to treat prostate cancer ...
In a rare move, nonprofit organization Blood Cancer United is buying the remaining supplies of a discontinued investigational ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results